- Conditions
- Mucinous Pancreatic Cysts
- Interventions
- Ethanol, Normal Saline, Chemotherapy
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1321–1344
of 2,451
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Crofelemer
- Drug
- Lead sponsor
- Sandra Swain
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey
- Conditions
- Breast Cancer
- Interventions
- Herceptin, Taxol, Adriamycin, Cytoxan
- Drug
- Lead sponsor
- Harold J. Burstein, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Solid Tumors
- Interventions
- VVD-130037, Docetaxel, Paclitaxel, Pembrolizumab
- Drug
- Lead sponsor
- Vividion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Sarasota, Florida • Tampa, Florida + 5 more
- Conditions
- Angiosarcoma of Skin
- Interventions
- Oraxol
- Drug
- Lead sponsor
- Athenex, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- New York, New York • Dallas, Texas • Houston, Texas + 1 more
- Conditions
- Breast Cancer
- Interventions
- carboplatin, paclitaxel
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Ovarian Cancer
- Interventions
- Azacitidine
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Maywood, Illinois • Winfield, Illinois
- Conditions
- Advanced Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Abdominal Neoplasm, Advanced Malignant Female Reproductive System Neoplasm, Advanced Malignant Thoracic Neoplasm, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Abdominal Neoplasm, Malignant Solid Neoplasm, Metastatic Breast Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Abdominal Neoplasm, Metastatic Malignant Female Reproductive System Neoplasm, Metastatic Malignant Thoracic Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Renal Cell Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
- Interventions
- Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel, Tumor Treating Fields Therapy
- Biological · Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
- Interventions
- Anvumetostat, Gemcitabine, Nab-paclitaxel, Modified FOLFIRINOX, RMC-6236
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 29
- States / cities
- Bakersfield, California • Duarte, California • La Jolla, California + 24 more
- Conditions
- Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
- Interventions
- Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Topotecan, Trametinib Dimethyl Sulfoxide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 488
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 310 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Everolimus, Trastuzumab, Paclitaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 11
- States / cities
- *see Various Departments*, California • Fountain Valley, California • Loma Linda, California + 8 more
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Ramucirumab, Paclitaxel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 7
- States / cities
- Duarte, California • Westwood, Kansas • Boston, Massachusetts + 4 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
- Interventions
- Docetaxel, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 482
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 309 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel, paclitaxel poliglumex
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 31 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery, Milestone 3: Chemoradiotherapy (cXRT), Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery, Milestone 4: Chemoradiotherapy (cXRT), Milestone 5: Targeted chemotherapy after surgery, Milestone 5: Chemoradiotherapy (cXRT), Milestone 6: Gemcitabine after surgery, Milestone 6: Chemoradiotherapy (cXRT), Milestone 7: Chemoradiotherapy (cXRT), Milestone 8: Targeted chemotherapy after surgery, Milestone 9: Gemcitabine after surgery, Milestone 10: No additional therapy after surgery
- Drug · Radiation · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Milwaukee, Wisconsin
- Conditions
- CNS Germ Cell Tumor
- Interventions
- Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Los Angeles, California • New York, New York + 1 more
- Conditions
- Breast Neoplasms, Metastases, Neoplasm
- Interventions
- ABI-007
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Gemcitabine, Albumin-bound paclitaxel
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Baltimore, Maryland + 2 more
- Conditions
- Intraocular Melanoma
- Interventions
- nab-paclitaxel
- Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pancreatic Cancer
- Interventions
- ANO31905, Nanoparticle Albumin-Bound Paclitaxel, Gemcitabine
- Biological · Drug
- Lead sponsor
- Anova Innovation Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Coronary Artery Disease
- Interventions
- Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Bakersfield, California • La Jolla, California + 24 more
- Conditions
- Ovarian Cancer
- Interventions
- Intraperitoneal tgDCC-E1A, Paclitaxel
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Nashville, Tennessee
- Conditions
- Lung Cancer, Neurotoxicity, Ovarian Cancer
- Interventions
- amifostine trihydrate, carboplatin, paclitaxel
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1998
- U.S. locations
- 4
- States / cities
- San Francisco, California